Cheson Bruce D, Bennett John M, Kopecky Kenneth J, Büchner Thomas, Willman Cheryl L, Estey Elihu H, Schiffer Charles A, Doehner Hartmut, Tallman Martin S, Lister T Andrew, Lo-Coco Francesco, Willemze Roel, Biondi Andrea, Hiddemann Wolfgang, Larson Richard A, Löwenberg Bob, Sanz Miguel A, Head David R, Ohno Ryuzo, Bloomfield Clara D
Department of Hematology/Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA.
J Clin Oncol. 2003 Dec 15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036.
An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials. Since the original publication, there have been major advances in our understanding of the biology and molecular genetics of acute leukemia that are clinically relevant and warrant incorporation into response definitions. Differences from the 1990 recommendations included a category of leukemia-free state, new criteria for complete remission, including cytogenetic and molecular remissions and remission duration. Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders.
一个国际工作组召开会议,修订了1990年首次发布的急性髓系白血病的诊断和反应标准,并提供了结局定义和报告标准,以提高数据的可解释性以及各试验之间的可比性。自最初发布以来,我们对急性白血病生物学和分子遗传学的理解取得了重大进展,这些进展具有临床相关性,值得纳入反应定义中。与1990年的建议不同之处包括无白血病状态类别、完全缓解的新标准,包括细胞遗传学和分子缓解以及缓解持续时间。储存活细胞用于相关研究对于这些疾病治疗的未来进展很重要。